In particular, we have provided strong evidence that the underlying mechanism of action of S109 involves a perturbation of the three core pathways in human glioma cells that is mediated by the nuclear retention of tumor-suppressor proteins. The gene discussed is TCHP; the disease is central nervous system cancer.